WuXi Biologics has begun the construction of new biologics drug substance manufacturing facility in Ireland on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth.
 
Being the company’s first site outside of China that is supported by the Irish Government through IDA Ireland, this state-of-the-art “facility of the future” is designed to run both traditional fed-batch or perfusion process and continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this 26-hectare campus. When completed, a total capacity of 48,000L fed-batch and 6,000L perfusion will be installed, representing one of the world’s largest facility using single-use bioreactors, according to the company.
 
“We are excited to witness the construction of WuXi Biologics’ first global site today,” said Chris Chen, chief executive officer, WuXi Biologics. “The commencement of this new facility symbolizes the significant start of our global biomanufacturing network to make sure that biologics can be manufactured at the highest quality, providing a robust supply chain to benefit patients worldwide. With this new project, we can actively work with all local partners to build this state-of-the-art biomanufacturing facility as a showcase to the entire global biotech community.”